Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcriptomic study first, on cryopreserved tumor samples. Then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain RNA transcripts and progression-free survival). Finally, set up immunohistochemical applications, which can be used routinely by the pathologist.
Study Type
OBSERVATIONAL
Enrollment
85
Guillaume GAUCHOTTE
Vandœuvre-lès-Nancy, Lorraine, France
Progression-free survival
Progression being defined by a growth (mm3) of the tumor objectified by imaging.
Time frame: through study completion an average of 5 years.
Tumor volume assessed by imaging pre- and post-operative
mm3; RECIST criteria
Time frame: before and within 3 months after surgery
mRNA quantities of transcripts of interest
µg.mL-1
Time frame: through study completion, an average of 1 year
Radiotherapy-induced toxicity
CTCAE scale (Common Terminology Criteria for Adverse Events) v 4.0
Time frame: within 5 years after radiotherapy
Dose of corticosteroids before and after radiotherapy
in mg
Time frame: within 6 months before and after radiotherapy
Intra-observer, inter-observer and inter-laboratory intra-class correlation coefficients of immunohistochemical markers.
Kappa coefficient
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.